Concizumab
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Concizumab |
| DrugBank ID | DB12820 |
| Brand Names (EU) | Alhemo |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 98.27% |
Approved Indication (EMA)
Alhemo is indicated for routine prophylaxis of bleeding in patients 12 years of age or more with: • haemophilia A (congenital factor VIII deficiency) with FVIII inhibitors.• severe haemophilia A (congenital factor VIII deficiency, FVIII < 1%) without FVIII inhibitors.• haemophilia B (congenital factor IX deficiency) with FIX inhibitors.• moderate/severe haemophilia B (congenital factor IX deficiency, F
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | diabetic cataract | 98.27% | DL |
| 2 | tetanic cataract | 98.16% | DL |
| 3 | mature cataract | 98.16% | DL |
| 4 | immature cataract | 98.16% | DL |
| 5 | diabetes mellitus type 2 associated cataract | 98.16% | DL |
| 6 | craniostenosis cataract | 98.16% | DL |
| 7 | nuclear senile cataract | 98.14% | DL |
| 8 | cortical cataract | 98.14% | DL |
| 9 | antithrombin deficiency type 2 | 98.12% | DL |
| 10 | senile cataract | 98.07% | DL |
| 11 | factor 5 excess with spontaneous thrombosis | 98.07% | DL |
| 12 | heparin cofactor 2 deficiency | 98.03% | DL |
| 13 | diabetic retinopathy | 97.98% | DL |
| 14 | thrombophilia | 97.76% | DL |
| 15 | severe nonproliferative diabetic retinopathy | 97.71% | DL |
| 16 | diffuse gastric adenocarcinoma | 95.41% | DL |
| 17 | hemorrhagic disease of newborn | 94.77% | DL |
| 18 | gastric carcinoma | 94.71% | DL |
| 19 | bronchitis | 94.71% | DL |
| 20 | gastric adenocarcinoma and proximal polyposis of the stomach | 94.69% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.